[go: up one dir, main page]

KR900007412A - 약제학적 조성물 - Google Patents

약제학적 조성물 Download PDF

Info

Publication number
KR900007412A
KR900007412A KR1019890016872A KR890016872A KR900007412A KR 900007412 A KR900007412 A KR 900007412A KR 1019890016872 A KR1019890016872 A KR 1019890016872A KR 890016872 A KR890016872 A KR 890016872A KR 900007412 A KR900007412 A KR 900007412A
Authority
KR
South Korea
Prior art keywords
component
pharmaceutical composition
polyoxyethylene glycol
group
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019890016872A
Other languages
English (en)
Inventor
옥산나 바신스키 마리아
하워드 인펠드 미틴
샤 나프니트
우노우스키 죠엘
Original Assignee
쟝-자끄 오가이, 롤란드 보러
에프.호프만-라 롯슈 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝-자끄 오가이, 롤란드 보러, 에프.호프만-라 롯슈 에이지 filed Critical 쟝-자끄 오가이, 롤란드 보러
Publication of KR900007412A publication Critical patent/KR900007412A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

내용 없음

Description

약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 약제학적으로 불활성인 담체의 존재 또는 부재하에 (a) 항균성 화합물 (b) 흡수 중진량의 2-성분 흡수 중진계를 함유하며, 여기서, 2-성분 흡수 증진계 (b)는 (1)(C6-C18)알콜과 폴리옥시에틸렌 글리콜의 에테르인 제1성분, 및 (2)(ⅰ)폴리옥시에틸렌 글리콜-(C6-C18)카복실산 글리세라이드 에스테르, (ⅱ)(C6-C18)카복실산 또는 약제학적으로 허용되는 이의 염, 및 (ⅲ)2개 이상의 (C6-C18)카복실산, 글리세롤 및 폴리옥시에틸렌 글리콜의 에스테르 중에서 선택된 제2성분으로 이루어짐을 특징으로 하는 약제학적 조성물.
  2. 제1항에 있어서, 흡수 중진계가 성분 (b)는 (1)(C6-C18)알콜과 폴리옥시에틸렌 글리콜의 에테르, 및 성분(b) (2)(ⅰ)폴리옥시에틸렌 글리콜-(C6-C18)카복실산 글리세라이드 에스테르로 이루어지는 약제학적 조성물.
  3. 제2항에 있어서, 성분(b)(1)이 라우릴 알콜과 폴리옥시에틸렌 글리콜의 에테르이고, 성분(b)(2)(ⅰ)이 폴리옥시에틸렌글리콜-8 카프릴레이트/카프레이트 글리세라이드 에스테르인 약제학적 조성물.
  4. 제1항에 있어서, 흡수 중진계가 성분(b)(1)인 (C6-C18) 알콜과 폴리옥시에틸렌 글리콜의 에테르, 및 성분(b)(2)(ⅱ)인 (C6-C18)카복실산 또는 약제학적으로 허용되는 이의 염으로 이루어지는 약제학적 조성물.
  5. 제4항에 있어서, 성분(b)(1)이 라우릴 알콜과 폴리옥시에틸렌 글리콜의 에테르이고, 성분(b)(2)(ⅱ)가 카프릴산 나트륨이 약제학적 조성물.
  6. 제1항에 있어서, 흡수 중진계가 성분(b)(1)인 (C6-C18) 알콜과 폴리옥시에틸렌 글리콜의 에테르, 및 성분(b)(2)(ⅱ)인 2개 이상의 (C6-C18)카복실산, 글리세롤 및 폴리옥시에틸렌 글리콜의 에스테르로 이루어지는 약재학적 조성물.
  7. 제6항에 있어서, 성분(b)(1)이 라우릴 알콜과 폴리옥시에틸렌 글리콜의 에테르이고, 성분(b)(2)(ⅱ)폴리옥시에틸렌 글리콜 글리세롤 코코에이트인 약재학적 조성물.
  8. 제7항에 있어서, 항균성 화합물이 β-락탐인약제학적 조성물.
  9. 제8항에 있어서, β-락탐이 하기 일반식의 화합물인 약제학적 조성물.
    상기식에서, R1은 수소 또는 임의로 치환된 알킬이고, R2는 일반식 SO- 3M+의 그룹이거나, R1과 R2는 이들이 결합된 β-락탐(아제티디논)과 환과 함께 일반식의 화합물을 나타내며,
    M+는 양성자 또는 양이온이고, R3은 아실아미노 그룹 또는 하이드록시알킬 그룹이며, X는 -S-, -O-, -SO-, -SO2-, -CH2또는 -CH(CH3)이고,
    Y는 일반식
    R4는 치환된 티오 그룹(이는 에틸티오, -SCH2CH2NH2,
    중에서 선택된다. 임의로 치환된 저급 알킬 그룹(이는 아미노메틸, 아실아미노메틸 및중에서 선택된다) 도는 카바모일옥시
    O
    (-OCVH2)와 같은 치환된 옥시그룹이고, -COOE그룹과 연결되어있는 탄소원자는 β-락탐환의 질소 원자에 결합되어 있으며, Z는 수소, 할로겐, 알콕시 또는 일반식(CH2T의 그룹이고, T는 수소, 알킬-CO-O-,피리디늄, 카복스아미도 피리디늄, 아미노피리디늄, 카바모일옥시, 아지도, 시아노, 하이드록실, 치환 가능한 -S-페닐 그룹 또는 -S-het그룹(여기서, "het"는 임의로 치환된 5- 또는 6-원 헤테로사이클릭환이다)이며, E는 수소, 약제학적으로 허용되는 에스테르 그룹 또는 염-형성 양이온이다.
  10. 제8항에있어서, 항균성 화합물이(E)-2-(이소부톡시카보닐)-2-펜테닐(6R,7R)-7-[(Z)-2(2-아미노-4-티아졸린)-2-(메톡시이미노)아세트아미도]-3-(아지도메틸)-8-옥소-5-티아-1-아자비사이클로[4,2,0]옥트-2-엔-2-카복실레이트인 약제학적 조성물.
  11. 제10항에 있어서, 항균성 화합물이 세프트리악손 또는 약제학적으로 허용되는 이의 염, 에스테르 또는 수화물인 약제학적 조성물.
  12. 제1항 내지 11항중 어느 한 항에 있어서, 피복된 장용 경구 투여 형태로 존재하는 약제학적 조성물.
  13. 제1항 내지 11항중 어느 한 항에 있어서, 직장투여 형태로 존재하는 약제학적 조성물.
  14. 전술된 바와 같은 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890016872A 1988-11-22 1989-11-21 약제학적 조성물 Ceased KR900007412A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27459088A 1988-11-22 1988-11-22
US274,590 1988-11-22

Publications (1)

Publication Number Publication Date
KR900007412A true KR900007412A (ko) 1990-06-01

Family

ID=23048828

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890016872A Ceased KR900007412A (ko) 1988-11-22 1989-11-21 약제학적 조성물

Country Status (15)

Country Link
EP (1) EP0370481B1 (ko)
JP (1) JPH0774165B2 (ko)
KR (1) KR900007412A (ko)
AT (1) ATE94765T1 (ko)
AU (1) AU625276B2 (ko)
CA (1) CA2003340A1 (ko)
DE (1) DE58905681D1 (ko)
DK (1) DK585889A (ko)
HU (1) HU205713B (ko)
IE (1) IE63119B1 (ko)
IL (1) IL92357A (ko)
NZ (1) NZ231447A (ko)
PH (1) PH26390A (ko)
YU (1) YU221889A (ko)
ZA (1) ZA898331B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115849A1 (de) * 1991-05-15 1992-11-19 Lohmann Therapie Syst Lts Penetrationsfoerdernde substanz
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SI9400338A (en) * 1994-08-31 1996-04-30 Lek D D Vancomycin hydrochloride suspensions for peroral use and for filling into soft ,gelatine capsules.
JPH08208510A (ja) * 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2681300A (en) * 1999-02-22 2000-09-14 Elan Corporation, Plc Solid oral dosage form containing an enhancer
WO2002092616A1 (en) 2001-05-11 2002-11-21 Orasense, Ltd. Antisense permeation enhancers
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20090280169A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
GB2482810A (en) 2008-09-17 2012-02-15 Chiasma Inc Enhanced delivery of exenatide using a medium chain fatty acid and salt thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Iii・リミテッド 経口投与用の鉄の医薬組成物
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
ES3029566T3 (en) 2015-02-03 2025-06-24 Amryt Endo Inc Treating acromegaly with oral octreotide
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1168949A (en) * 1979-08-13 1984-06-12 William G. Gorman Cleansing compositions
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS59212427A (ja) * 1983-05-19 1984-12-01 Kyoto Yakuhin Kogyo Kk 直腸投与用組成物
EP0126348A2 (en) * 1983-05-19 1984-11-28 Kyoto Pharmaceutical Industries, Ltd. Composition for rectal administration and method of promoting rectal drug absorption
CA1256799A (en) * 1984-02-22 1989-07-04 Walter Fuller Suppositories
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs

Also Published As

Publication number Publication date
PH26390A (en) 1992-07-02
IE63119B1 (en) 1995-03-22
JPH0774165B2 (ja) 1995-08-09
HUT52374A (en) 1990-07-28
HU205713B (en) 1992-06-29
DE58905681D1 (de) 1993-10-28
ATE94765T1 (de) 1993-10-15
EP0370481B1 (de) 1993-09-22
YU221889A (en) 1992-05-28
CA2003340A1 (en) 1990-05-22
EP0370481A2 (de) 1990-05-30
HU896123D0 (en) 1990-02-28
AU625276B2 (en) 1992-07-09
IL92357A (en) 1994-10-07
EP0370481A3 (de) 1991-01-16
JPH02180837A (ja) 1990-07-13
DK585889A (da) 1990-05-23
IL92357A0 (en) 1990-07-26
AU4538489A (en) 1990-05-31
NZ231447A (en) 1992-09-25
ZA898331B (en) 1990-07-25
IE893718L (en) 1990-05-22
DK585889D0 (da) 1989-11-21

Similar Documents

Publication Publication Date Title
KR900007412A (ko) 약제학적 조성물
ATE4903T1 (de) 1-, 6- und 2-substituierte 1-carba-2-penem-3carbons[ure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
NL930130I1 (nl) Nieuwe cefalosporine-derivaten werkwijze ter bereiding daarvan en als antibiotica bruikbare geneesmiddelen deze derivaten bevatten
KR920002622A (ko) 9-푸리닐 포스폰산 유도체
PT531875E (pt) Diastereomeros do ester 1-(isopropoxicarboniloxi)-etilico do acido 3-cefem-4-carboxilico e processo para a sua preparacao
KR890014562A (ko) 아실 유도체
IL70457A (en) 3-alkyl-4-acyl-thieno(2,3-b)-pyrrole-6-acetic acid derivatives,their preparation and pharmaceutical compositions containing them
DE3381734D1 (de) Thiazolylessigsaeure-derivate und verfahren zu deren herstellung.
PH20392A (en) Pyridobenzodiazepinones pharmaceutical compositions thereof and method of use thereof
EP0054512A3 (de) Cephalosporinester, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
KR920004401A (ko) 신규한 세팔로스포린 화합물과 그의 제조방법
NO159857C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive cephalosporinderivater i syn-form.
ATE33392T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung und sie enthaltende antibiotische medikamente.
KR910005870A (ko) 약제학적 제제
ES8609322A1 (es) Un procedimiento de obtencion de imidazoquinolinas
JPS57136586A (en) Cephalosporin derivative and its preparation
FR2572404B2 (fr) Nouveaux derives de l'acide 4-oh-3-quinoleine carboxylique substitues en 2, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
EP0000644A3 (en) Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions
KR900018118A (ko) 신규 세팔로스포린계 항생제 및 이의 제조방법
KR910015585A (ko) 신규한 세팔로스포린 화합물과 그의 제조방법
KR840005151A (ko) 세팔로스포린 항생물질의 제조방법
ATE30592T1 (de) Penicillinderivate.
KR910000750A (ko) 신규 세팔로스포린계 항생제 및 이의 제조 방법
JPS52122391A (en) Novel penicillins
SE8105628L (sv) Cefalosporinderivat

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19891121

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19941121

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19891121

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19971118

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980421

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19971118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I